Morgan Stanley assumed coverage of Disc Medicine (IRON) with an Overweight rating and $85 price target The near-term focus is on bitopertin with the new drug application submission under the accelerated approval pathway in 2H25 and DISC-0974 data expected in December, the analyst tells investors in a research note. The firm models a 2026 launch for bitopertin and $1.3B in unadjusted U.S. peak sales for bitopertin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Promising Future: Buy Rating Backed by Strong Pipeline and Growth Potential
- Promising Potential of Bitopertin in Treating Erythropoietic Protoporphyria Drives Buy Rating for Disc Medicine
- Disc Medicine’s Promising Hematology Pipeline and Positive Trial Results Earn Buy Rating
- Top Analysts Pound the Table on These Three Stocks, 6/18/2025
- Promising Potential of Disc Medicine’s Bitopertin Drives Buy Rating